BHC
Bausch Health Companies Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$2.11B
5Y Perf.-69.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BHC vs PBH
Revenue, margins, valuation, and 5-year total return — side by side.
PBH
Prestige Consumer Healthcare Inc.
Medical - Distribution
Market Cap$2.57B
5Y Perf.+29.4%
BHC vs PBH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BHC | PBH |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Distribution |
| Market Cap | $2.11B | $2.57B |
| Revenue (TTM) | $10.55B | $1.10B |
| Net Income (TTM) | $-1.19B | $187M |
| Gross Margin | 61.7% | 56.4% |
| Operating Margin | 22.9% | 29.2% |
| Forward P/E | 1.3x | 12.0x |
| Total Debt | $21.21B | $1.04B |
| Cash & Equiv. | $1.32B | $98M |
BHC vs PBH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BHC
PBH
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bausch Health Compa… (BHC) | 100 | 31.0 | -69.0% |
| Prestige Consumer H… (PBH) | 100 | 129.4 | +29.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BHC vs PBH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BHC and PBH are tied at the top with 3 categories each — the right choice depends on your priorities. Prestige Consumer Healthcare Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BHC
Bausch Health Companies Inc.
The Growth Play
BHC has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 8.5%, EPS growth 430.8%, 3Y rev CAGR 8.7%
- 8.5% revenue growth vs PBH's 1.1%
- Lower P/E (1.3x vs 12.0x)
Best for: growth exposure
PBH
Prestige Consumer Healthcare Inc.
The Income Pick
PBH is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.53
- -3.4% 10Y total return vs BHC's -81.1%
- Lower volatility, beta 0.53, Low D/E 56.9%, current ratio 4.20x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BHC | 8.5% revenue growth vs PBH's 1.1% |
| Value | BHC | Lower P/E (1.3x vs 12.0x) |
| Quality / Margins | PBH | 16.9% margin vs BHC's -11.3% |
| Stability / Safety | PBH | Beta 0.53 vs BHC's 1.02, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BHC | +19.2% vs PBH's -33.0% |
| Efficiency (ROA) | PBH | 5.3% ROA vs BHC's -4.5%, ROIC 9.1% vs 8.2% |
BHC vs PBH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
BHC vs PBH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPBHLAGGINGBHC
BHCBausch Health Compani…
1leads
PBHPrestige Consumer Hea…
2leads
6 Total Categories
CATEGORYLEADERvs BHCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PBH4/6
Valuation MetricsMultiples, price ratios, and targets
BHC4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PBH7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PBH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BHC is the larger business by revenue, generating $10.6B annually — 9.6x PBH's $1.1B. PBH is the more profitable business, keeping 16.9% of every revenue dollar as net income compared to BHC's -11.3%. On growth, BHC holds the edge at +10.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| RevenueTrailing 12 months | $10.6B | $1.1B |
| EBITDAEarnings before interest/tax | $3.6B | $353M |
| Net IncomeAfter-tax profit | -$1.2B | $187M |
| Free Cash FlowCash after capex | $990M | $267M |
| Gross MarginGross profit ÷ Revenue | +61.7% | +56.4% |
| Operating MarginEBIT ÷ Revenue | +22.9% | +29.2% |
| Net MarginNet income ÷ Revenue | -11.3% | +16.9% |
| FCF MarginFCF ÷ Revenue | +9.4% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.5% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.7% | -20.5% |
PBH leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BHC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 12.7x trailing earnings, PBH trades at a 4% valuation discount to BHC's 13.1x P/E. On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than PBH's 9.6x.
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| Market CapShares × price | $2.1B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $22.0B | $3.5B |
| Trailing P/EPrice ÷ TTM EPS | 13.14x | 12.66x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.32x | 12.02x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.40x |
| EV / EBITDAEnterprise value multiple | 6.37x | 9.58x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 2.26x |
| Price / BookPrice ÷ Book value/share | 5.63x | 1.48x |
| Price / FCFMarket cap ÷ FCF | 2.10x | 10.56x |
BHC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
PBH leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $10 for PBH. PBH carries lower financial leverage with a 0.57x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), PBH scores 8/9 vs BHC's 7/9, reflecting strong financial health.
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| ROE (TTM)Return on equity | +5.9% | +10.2% |
| ROA (TTM)Return on assets | -4.5% | +5.3% |
| ROICReturn on invested capital | +8.2% | +9.1% |
| ROCEReturn on capital employed | +10.6% | +10.4% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 8 |
| Debt / EquityFinancial leverage | 56.36x | 0.57x |
| Net DebtTotal debt minus cash | $19.9B | $946M |
| Cash & Equiv.Liquid assets | $1.3B | $98M |
| Total DebtShort + long-term debt | $21.2B | $1.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.43x | 7.40x |
PBH leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — BHC and PBH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PBH five years ago would be worth $11,531 today (with dividends reinvested), compared to $2,035 for BHC. Over the past 12 months, BHC leads with a +19.2% total return vs PBH's -33.0%. The 3-year compound annual growth rate (CAGR) favors BHC at -1.9% vs PBH's -3.0% — a key indicator of consistent wealth creation.
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| YTD ReturnYear-to-date | -21.6% | -11.3% |
| 1-Year ReturnPast 12 months | +19.2% | -33.0% |
| 3-Year ReturnCumulative with dividends | -5.7% | -8.7% |
| 5-Year ReturnCumulative with dividends | -79.6% | +15.3% |
| 10-Year ReturnCumulative with dividends | -81.1% | -3.4% |
| CAGR (3Y)Annualised 3-year return | -1.9% | -3.0% |
Evenly matched — BHC and PBH each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BHC and PBH each lead in 1 of 2 comparable metrics.
Risk & Volatility
PBH is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than BHC's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BHC currently trades 65.0% from its 52-week high vs PBH's 60.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 0.53x |
| 52-Week HighHighest price in past year | $8.69 | $89.37 |
| 52-Week LowLowest price in past year | $4.41 | $51.24 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +60.8% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 41.0 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 473K |
Evenly matched — BHC and PBH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BHC as "Buy" and PBH as "Buy". Consensus price targets imply 41.6% upside for BHC (target: $8) vs 21.5% for PBH (target: $66).
| Metric | BHCBausch Health Com… | PBHPrestige Consumer… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $66.00 |
| # AnalystsCovering analysts | 38 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PBH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BHC leads in 1 (Valuation Metrics). 2 tied.
Best OverallPrestige Consumer Healthcar… (PBH)Leads 2 of 6 categories
Loading custom metrics...
BHC vs PBH: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BHC or PBH a better buy right now?
For growth investors, Bausch Health Companies Inc.
(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus 1. 1% for Prestige Consumer Healthcare Inc. (PBH). Prestige Consumer Healthcare Inc. (PBH) offers the better valuation at 12. 7x trailing P/E (12. 0x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BHC or PBH?
On trailing P/E, Prestige Consumer Healthcare Inc.
(PBH) is the cheapest at 12. 7x versus Bausch Health Companies Inc. at 13. 1x. On forward P/E, Bausch Health Companies Inc. is actually cheaper at 1. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BHC or PBH?
Over the past 5 years, Prestige Consumer Healthcare Inc.
(PBH) delivered a total return of +15. 3%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: PBH returned -3. 7% versus BHC's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BHC or PBH?
By beta (market sensitivity over 5 years), Prestige Consumer Healthcare Inc.
(PBH) is the lower-risk stock at 0. 53β versus Bausch Health Companies Inc. 's 1. 02β — meaning BHC is approximately 90% more volatile than PBH relative to the S&P 500. On balance sheet safety, Prestige Consumer Healthcare Inc. (PBH) carries a lower debt/equity ratio of 57% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BHC or PBH?
By revenue growth (latest reported year), Bausch Health Companies Inc.
(BHC) is pulling ahead at 8. 5% versus 1. 1% for Prestige Consumer Healthcare Inc. (PBH). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to 2. 9% for Prestige Consumer Healthcare Inc.. Over a 3-year CAGR, BHC leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BHC or PBH?
Prestige Consumer Healthcare Inc.
(PBH) is the more profitable company, earning 18. 9% net margin versus 1. 5% for Bausch Health Companies Inc. — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBH leads at 29. 6% versus 21. 3% for BHC. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BHC or PBH more undervalued right now?
On forward earnings alone, Bausch Health Companies Inc.
(BHC) trades at 1. 3x forward P/E versus 12. 0x for Prestige Consumer Healthcare Inc. — 10. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BHC: 41. 6% to $8. 00.
08Which pays a better dividend — BHC or PBH?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BHC or PBH better for a retirement portfolio?
For long-horizon retirement investors, Prestige Consumer Healthcare Inc.
(PBH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53)). Both have compounded well over 10 years (PBH: -3. 7%, BHC: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BHC and PBH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(BHC: 10.5% · PBH: -2.4%)P/E Ratio<
x
(BHC: 13.1x · PBH: 12.7x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.